Benzinga · Aug 17, 2026
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backed by a $245M private placement.
FU
NASDAQ · FULC
Fulcrum Therapeutics, Inc.
Healthcare · Biotechnology
$3.85
Up+$0.01 (+0.26%)
Updated Sep 8, 2026, 5:25 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 692.63M
- P/E ratio
- -11.27
- Dividend yield
- 0.00%
- 52-week range
- $2.83 – $8.37
- Volume
- 1M
- Avg. volume
- 1.17M
Price performance
FULC price history
1M range · 20 trading sessions · Daily adjusted prices
FULC closed at $3.85 after 20 trading sessions, up 2.67% for the selected period.
- Last close
- $3.85
- Period change
- +2.67%
- Period low
- $3.69
- Period high
- $3.91
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $3.81 | $3.855 | $3.80 | $3.85 | 1M |
| Sep 3, 2026 | $3.87 | $3.89 | $3.82 | $3.84 | 1.44M |
| Sep 2, 2026 | $3.88 | $3.90 | $3.825 | $3.85 | 1.63M |
| Sep 1, 2026 | $3.85 | $3.88 | $3.82 | $3.87 | 1.68M |
| Aug 31, 2026 | $3.83 | $3.915 | $3.796 | $3.89 | 1.8M |
| Aug 28, 2026 | $3.82 | $3.87 | $3.78 | $3.85 | 1.89M |
| Aug 27, 2026 | $3.86 | $3.89 | $3.825 | $3.85 | 785.02K |
| Aug 26, 2026 | $3.86 | $3.88 | $3.82 | $3.86 | 854.86K |
| Aug 25, 2026 | $3.87 | $3.89 | $3.835 | $3.86 | 1.32M |
| Aug 24, 2026 | $3.835 | $3.86 | $3.78 | $3.84 | 856.38K |
| Aug 21, 2026 | $3.85 | $3.90 | $3.78 | $3.83 | 1.51M |
| Aug 20, 2026 | $3.88 | $3.9072 | $3.81 | $3.85 | 1.2M |
| Aug 19, 2026 | $3.90 | $3.94 | $3.855 | $3.91 | 2.18M |
| Aug 18, 2026 | $3.85 | $3.90 | $3.745 | $3.87 | 2.75M |
| Aug 17, 2026 | $3.81 | $3.90 | $3.7514 | $3.84 | 8.44M |
| Aug 14, 2026 | $3.70 | $3.755 | $3.65 | $3.74 | 980.42K |
| Aug 13, 2026 | $3.75 | $3.76 | $3.64 | $3.71 | 1.36M |
| Aug 12, 2026 | $3.70 | $3.74 | $3.615 | $3.72 | 901.4K |
| Aug 11, 2026 | $3.77 | $3.775 | $3.655 | $3.69 | 804.12K |
| Aug 10, 2026 | $3.85 | $3.87 | $3.74 | $3.75 | 1.12M |
Latest FULC news
The latest Smart Investors Daily articles mentioning FULC.
Stock researchCompany · Overview
FULC research
Overview
Company profile and research snapshot.
Company profile
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $20.71
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 3, 2026 | JP Morgan | Underweight | — |
| Jun 2, 2026 | Truist Securities | Hold | — |
| Jun 2, 2026 | Piper Sandler | Underweight | — |
| Jun 2, 2026 | Stifel | Hold | — |
| Jun 2, 2026 | Leerink Partners | Market Perform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 17, 2026
Fulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeuticsSlate’s lead product candidate, SLTE-1009, is a clinical stage, potentially
Yahoo · Aug 5, 2026
Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit
The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share. This shift in price target sits against a backdrop of sharply changed Street commentary after the decision to discontinue pociredir, with more focus on cash, restructuring and the ongoing review of options than on late stage development potential. Read on to see how this evolving narrative could matter for your own view on Fulcrum Therapeutics and how to track the next set...
SeekingAlpha · Jul 31, 2026
Fulcrum Therapeutics: Buy It For The Strategic Reset
Fulcrum trades below NCAV amid operational distress but boasts a fortress balance sheetâexplore why this deep-discount setup could outperform.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
